Minerva Neurosciences, Inc.


Minerva Neurosciences to Present at Cowen and Company 37th Annual Health Care Conference on March 7, 2017

WALTHAM, Mass., 2017-02-28 14:30 CET (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Cowen and Company 37thAnnual Health Care Conference on March 7 at 10:40 a.m. Eastern Time.

The presentation will be web cast and accessible through the investor relations section of the Company’s web site,

About Minerva Neurosciences:

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-202 (JNJ-42847922), in clinical development for insomnia and adjunctive treatment of MDD, respectively; MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please


William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376

Information om Globenewswire

Nikolaj Plads 6
1007 København K

+45 3377 0377